Panacea Biotec gets USFDA’s approval for Rizatriptan Benzoate Tablet

18 Jan 2017 Evaluate

Panacea Biotec has received approval from US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) to market a generic version of Rizatriptan Benzoate Tablet, Orally Disintegrating, 5 mg and 10 mg.

This generic is equivalent to MAXALT-MLT ODT of Merck & Co. The current annual sales for Rizatriptan Benzoate Tablet, Orally Disintegrating, 5 mg and 10 mg in the US market is around $ 60 million. Rizatriptan Benzoate is a serotonin (5-HT) 1B/11) receptor against (triptan) indicated for the acute treatment of migraine in adults and in pediatric patients.

Further, the company is planning to launch the product within first quarter of 2017 through its distribution partner in US. Recently, the company got approval of its anti-cancer formulation facility from USFDA in November, 2016.

Panacea Biotec is one of the India’s leading research based health management companies with established research, manufacturing and marketing capabilities.
 


Panacea Biotec Share Price

344.65 -0.10 (-0.03%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×